Protein Summary
Probably involved in connections of major cytoskeletal structures to the plasma membrane. High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts (By similarity). This gene encodes a cytoskeletal protein that is concentrated in areas of cell-substratum and cell-cell contacts. The encoded protein plays a significant role in the assembly of actin filaments and in spreading and migration of various cell types, including fibroblasts and osteoclasts. It codistributes with integrins in the cell surface membrane in order to assist in the attachment of adherent cells to extracellular matrices and of lymphocytes to other cells. The N-terminus of this protein contains elements for localization to cell-extracellular matrix junctions. The C-terminus contains binding sites for proteins such as beta-1-integrin, actin, and vinculin. [provided by RefSeq, Feb 2009]
- ENST00000314888
- ENSP00000316029
- ENSG00000137076
- KIAA1027
- TLN
- TLN
- ILWEQ
- talin-1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
interacting protein | 1 | ||
protein domain | 1 | ||
transcription factor perturbation | 0.98 | ||
disease perturbation | 0.97 | ||
transcription factor binding site profile | 0.91 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 174.76 (req: < 5)
Gene RIFs: 103 (req: <= 3)
Antibodies: 625 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 174.76 (req: >= 5)
Gene RIFs: 103 (req: > 3)
Antibodies: 625 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 19
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0